Johns Hopkins Scientists Designing Compounds To Fight Malaria

Chemists have developed new compounds that show promise in treating malaria by making the disease-causing parasites self-destruct.

A scientific paper about the compounds will appear in the March 12 issue of the Journal of Medicinal Chemistry, published by the American Chemical Society.

At any given time, about 300 million people suffer from malaria, and as many as 3 million of them, mostly children, will die every year. The most severe form of the infection is caused by tiny parasites called Plasmodium falciparum, which are transmitted by female mosquitos feeding on human blood.

The drug of choice to combat malaria has been chloroquine, a derivative of quinine, which comes from the bark of the Cinchona tree. But the malaria parasites began showing resistance to chloroquine nearly 40 years ago.

Chinese chemists have isolated a new anti-malarial drug from the plant Artemisia annua, which has been used for thousands of years as an herbal remedy for fever. The drug, called artemisinin, has since been proven to be effective against malaria. Chemists have developed derivatives of artemisinin, as well. But artemisinin and its derivatives remain difficult and expensive to produce, and they quickly break down in the human body.

New synthetic compounds being developed at Johns Hopkins have been shown to kill malaria parasites in test tubes and in experiments with mice. Although the synthetic compounds use the same general mechanism as artemisinin, they are not derivatives of the drug; they are a new type of compound that has a much simpler structure. Because they are simpler, they can be made in only three to five chemical steps, compared to 12 or more steps for the artemisinin derivatives.

The research is being conducted by a team of scientists led by Gary H. Posner, Scowe Professor of Chemistry in The Johns Hopkins University School of Arts and Sciences, Theresa A. Sh

Contact: Emil Venere
Johns Hopkins University

Page: 1 2 3

Related biology news :

1. Yale professor receives Johnson & Johnson Focused Giving award
2. Marian Johnson-Thompson wins 2004 Alice C. Evans Award
3. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
4. Johns Hopkins gene hunters pinpoint new cancer gene target
5. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
6. Johns Hopkins receives $24 million from Donald W. Reynolds Foundation to study sudden cardiac death
7. Johns Hopkins researchers devise methods to evaluate disaster drills
8. Johns Hopkins scientists create forgetful mouse
9. A bed of microneedles: Johns Hopkins scientists gadget measures muscle cell force
10. Wake Forest-Johns Hopkins team discovers prostate cancer gene
11. The next generation of scientists recognized at Johns Hopkins

Post Your Comments:

(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... ... ... Group announced the opening of a new core patient care hub with the opening ... facilities are part of GSCG’s expansion efforts in Latin America. , Both the Arica ... patients from around the world. , The clinics will be headed by Victor Perez, M.D. ...
(Date:11/30/2015)... December 1, 2015 Partnership includes an ... for the u niversity , s ... treatment s cale - up ...   Africa , where licensees based anywhere in the world ... SDN technology. --> Africa , where licensees based anywhere in ...
(Date:11/30/2015)... Epigenetics Corp. ("Zenith" or the "Company") today announced that it ... Board of Directors to replace Dr. Peter Johann . ... as co-founder of Resverlogix, with expertise in the fields of ... --> Dr. Wong remarked, "I am very excited to ... expertise in epigenetics and the advanced stage of the R&D ...
(Date:11/30/2015)... N.J. , Nov. 30, 2015  Champions Oncology, ... solutions and services to personalize the development and use ... , Chief Executive Officer, will be presenting at the ... at 4:30pm Pacific Standard Time (PST).  The conference, held ... Los Angeles, CA , will feature 200 ...
Breaking Biology Technology:
Cached News: